Literature DB >> 18469031

Cerebrovascular dysplasia in neurofibromatosis type 1.

A G Cairns1, K N North.   

Abstract

OBJECTIVE: To assess the frequency and clinical characteristics of the increasingly recognised complication of cerebrovascular dysplasia in children with neurofibromatosis type 1 (NF1).
METHODS: A series of seven patients with NF1 and cerebrovascular dysplasias that were not secondary to radiotherapy were identified and prospectively assessed. An extensive review of the literature was also performed to identify associated features and the natural history of this potentially severe complication of NF1.
RESULTS: The frequency of cerebrovascular dysplasia in NF1 was found to be 2-5%, and vascular lesions were clearly visible on routine MRI of the brain. The majority of patients were clinically asymptomatic, despite angiographic progression in some cases. Hypoplastic carotid canals and early appearance on MRI suggested that a proportion of cases of cerebrovascular dysplasia were congenital in origin.
CONCLUSION: These findings have implications for screening of asymptomatic patients with NF1, and highlight the difficult management decisions in those patients identified with cerebrovascular malformations.

Entities:  

Mesh:

Year:  2008        PMID: 18469031     DOI: 10.1136/jnnp.2007.136457

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

3.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

4.  Moyamoya disease is a vascular form of neurocristopathy: disease of the embryologic cephalic neural crest.

Authors:  Masaki Komiyama
Journal:  Childs Nerv Syst       Date:  2017-03-15       Impact factor: 1.475

5.  Cerebral arteriopathy in neurofibromatosis type 1.

Authors:  Rk Sanjeev; S Kumaravelu
Journal:  Med J Armed Forces India       Date:  2012-01-18

Review 6.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

7.  Cardiac and vascular functions of the zebrafish orthologues of the type I neurofibromatosis gene NFI.

Authors:  Arun Padmanabhan; Jeong-Soo Lee; Fraz A Ismat; Min Min Lu; Nathan D Lawson; John P Kanki; A Thomas Look; Jonathan A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 8.  Cerebrovascular stenosis in neurofibromatosis type 1 and utility of magnetic resonance angiography: our experience and literature review.

Authors:  Felice D'Arco; Alessandra D'Amico; Ferdinando Caranci; Nilde Di Paolo; Daniela Melis; Arturo Brunetti
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

9.  Classic neuroimaging findings of nonketotic hyperglycemia on computed tomography and magnetic resonance imaging with absence of typical movement disorder symptoms (hemichorea-hemiballism).

Authors:  Barry G Hansford; Dara Albert; Edward Yang
Journal:  J Radiol Case Rep       Date:  2013-08-01

10.  Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1.

Authors:  Bonnie Kaas; Thierry A G M Huisman; Aylin Tekes; Amanda Bergner; Jaishri O Blakeley; Lori C Jordan
Journal:  J Child Neurol       Date:  2012-07-25       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.